ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer
ContraVir Pharmaceuticals Inc. is merging with competitor early stage hepatitis B drug developer Ciclofilin Pharmaceuticals to strengthen its pipeline offering in antivirals.
You may also be interested in...
While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.
At BioPharm America 2016, ContraVir CEO James Sapirstein explains how CMX157, a lipid formulation of tenofovir (Gilead's Viread for HIV and hepatitis B), could become a backbone agent for advances in combination therapy in hep B.
A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.